What Is ELV Fair Value?
Elevance Health (ELV) fair value estimate using multiple valuation models, updated daily.
As of August 29, 2026, Elevance Health (ELV) has a composite fair value estimate of $331.22 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $394.43, suggesting the stock is overvalued by 16.0%.
Data as of August 29, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$331.22
vs. current price of $394.43(-16.0%)
How Is ELV Fair Value Calculated?
Four independent models estimate what ELV is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ELV Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$383.02
-2.9%Fair Value
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$111.28
-71.8%Overvalued
Inputs used
ELV Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$355.65
-9.8%Fair Value
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$271.60
-31.1%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $394.43 is 2.9% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $4.39B | $4.10B |
| Year 2 | $4.48B | $3.90B |
| Year 3 | $4.57B | $3.72B |
| Year 4 | $4.66B | $3.54B |
| Year 5 | $4.75B | $3.37B |
| Year 6 | $4.85B | $3.21B |
| Year 7 | $4.95B | $3.05B |
| Year 8 | $5.05B | $2.90B |
| Year 9 | $5.15B | $2.77B |
| Year 10 | $5.25B | $2.63B |
| Terminal Value | $115.81B | $58.07B |
What Are ELV's Key Financial Metrics?
Earnings & Growth
Current Price
$394.43
EPS (TTM)
$22.36
Forward P/E
13.3
Profit Margin
2.5%
Cash & Balance Sheet
Free Cash Flow
4.3B
EBITDA
8.3B
Book Value
$206.99
Total Debt
31B
What Do Analysts Say About ELV?
Low
$393.00
Average
$449.10
High
$492.00
Upside
+13.9%
ELV Fair Value FAQ
What is the fair value of ELV?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ELV's estimated fair value is $331.22. The stock is currently trading at $394.43, which makes it overvalued by our analysis.
How is ELV's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ELV overvalued or undervalued?
Based on our analysis, ELV is overvalued. The current price of $394.43 is 16.0% above our estimated fair value of $331.22.
What do Wall Street analysts say about ELV?
21 analysts cover Elevance Health with a consensus rating of "Buy." The average price target is $449.10, ranging from $393.00 to $492.00. This implies 13.9% upside from the current price.